Large-Scale Proteomics and Multiomics Biomarker Discovery Tech Note

Large-Scale Proteomics and Multiomics Biomarker Discovery Research

Biomarker identification has long served as a foundation for accelerating drug discovery and development, from early preclinical research through clinical development and regulatory approval. The emergence of mid- to high-plex protein detection and quantification strategies enables broader and more effective use of protein biomarkers across the drug discovery pipeline. Using Olink® Proximity Extension Assay (PEA) technology, GENEWIZ from Azenta Life Sciences delivers fully validated, high-plex protein biomarker discovery services, generating up to one million data points per experiment with sensitivity comparable to traditional methods—while requiring significantly lower sample input.

In this tech note, explore the scientific principles behind the Olink PEA assay and learn how its scalable, high-throughput design simplifies the integration of protein biomarker discovery into both preclinical and clinical research, as well as proteomics and multiomics studies.

What you'll learn:

• Discover key applications for high-plex proteomics across drug discovery, translational research, and clinical studies
• Explore the capabilities of multiplexed and high-plex Olink Explore Panels, including broad pathway coverage and low sample requirements
• Review the results of GENEWIZ’s supplementary performance study evaluating the Olink Explore 3072 Assay, including reproducibility, sensitivity, and concordance with targeted assays